Literature DB >> 26961211

Atypical pathogen infection in community-acquired pneumonia.

Yun Yu1, Aihua Fei.   

Abstract

Community-acquired pneumonia (CAP) is a world wide cause of morbidity and mortality. The etiology of CAP is different between countries and changes over time. With the increasing incidence, atypical pathogens are attracting more and more attention all over the world. In many countries, atypical pathogens are one of the main pathogens of CAP, and even could be the most prevalent etiology in China. Atypical pathogen infections can cause multi-system complications, which leads to a worse prognosis. Although still controversial, empirical antibiotic coverage of atypical pathogens in CAP may improve outcomes, shorten length of hospitalization, reduce mortality and lower total hospitalization costs. The macrolide resistance rate of atypical pathogens, especially Mycoplasma Pneumoniae (M. Pneumoniae) is high, so fluoroquinolones or tetracyclines should be considered as alternative therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26961211     DOI: 10.5582/bst.2016.01021

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  8 in total

Review 1.  Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.

Authors:  Lokesh Sharma; Ashley Losier; Thomas Tolbert; Charles S Dela Cruz; Chad R Marion
Journal:  Clin Chest Med       Date:  2016-12-24       Impact factor: 2.878

Review 2.  Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.

Authors:  Sachin S Bhagwat; Manohar Nandanwar; Atul Kansagara; Anusuya Patel; Swapna Takalkar; Rajesh Chavan; Hariharan Periasamy; Ravindra Yeole; Prasad K Deshpande; Satish Bhavsar; Ashima Bhatia; Jaishid Ahdal; Rishi Jain; Mahesh Patel
Journal:  Drug Des Devel Ther       Date:  2019-12-24       Impact factor: 4.162

Review 3.  Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.

Authors:  Roopali Sharma; Christian E Sandrock; Joni Meehan; Nicolette Theriault
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

4.  The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study.

Authors:  Hong-Yan Liu; Hui-Xian Xiang; Ying Xiang; Zheng Xu; Chun-Mei Feng; Jun Fei; Lin Fu; Hui Zhao
Journal:  BMC Infect Dis       Date:  2021-04-07       Impact factor: 3.090

5.  The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-κB signal pathway.

Authors:  Qun Zhang; Junyao Li; Haixia Zhong; Yanling Xu
Journal:  Mol Med       Date:  2021-09-20       Impact factor: 6.354

6.  Characteristics of the lung microbiota in lower respiratory tract infections with and without history of pneumonia.

Authors:  Lingling Hong; Yuqing Chen; Ling Ye
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Emergent Virus Reactivation in SARS-CoV-2-Negative Community Acquired Pneumonia Patients During the COVID-19 Pandemic.

Authors:  Junyan Qu; Fang He; Huan Li; Xiaoju Lv
Journal:  Front Microbiol       Date:  2022-02-07       Impact factor: 5.640

8.  Current perspectives on atypical pneumonia in children.

Authors:  Jung Yeon Shim
Journal:  Clin Exp Pediatr       Date:  2020-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.